• Single dose of R-salbutamol produces significant improvements in by lindayy

VIEWS: 371 PAGES: 3

• Single dose of R-salbutamol produces significant improvements in ...

More Info
									              ANNOUNCEMENT TO AUSTRALIAN STOCK EXCHANGE

                                    16 FEBRUARY 2007

 R-SALBUTAMOL CONFIRMED AS EFFECTIVE TREATMENT FOR HORSES WITH
                    EQUINE AIRWAY DISEASE

       •           Single dose of R-salbutamol produces significant
                   improvements in lung function and breathing for horses
                   with heaves.
       •           Beneficial effects to distressed horses.

Stirling Products (ASX:STI) advises shareholders that it has now completed a second
study of R-salbutamol in horses with airway disease “heaves”, the most common chronic
respiratory disease of horses. The new study confirms that R- salbutamol is an excellent
rescue medication for horses that cannot breathe normally because of acute
bronchoconstriction. Heaves is the most common chronic disease in horses in the
northern hemisphere and it is estimated that close to 30% of all horses in the US suffer
from heaves.

The first study, reported last month (ASX Announcement January 18), demonstrated that
R-salbutamol is more effective than anticipated for the treatment of chronic heaves in
horses. The present study has shown excellent effects in acutely sick horses even when
a single dose of R-salbutamol is administered to the animals. In all these studies, R-
salbutamol has been administered with the specialised delivery system for horses called
the EquineHaler™.

“This study confirms that when horses with heaves receive a single low dose of R-
salbutamol, there is a dramatic improvement in both clinical scores and lung function,”
indicated Dr Calvin London, CEO and Managing Director of Stirling Products “As in the
first study, no increase in sweating, trembling, or excitement occurred at either of the
doses used,” he added.

Heaves is characterised by an inability of the horses to expel air from the lungs, resulting
in decreased performance during competition or exercise. Equine respiratory vets treat
the acute symptoms of heaves with drugs that provide an immediate relief for the
animal's distress. Drugs that are effective for treatment of heaves are also very
beneficial for treatment of the less severe forms of airway inflammation that occur in
about 20% of horses.



                                         ABN 32 077 105 429
                      Level 11, BGC Centre, 28 The Esplanade, Perth WA 6000
                                Tel: 08 9480 1480 Fax: 08 9226 4144
“This means that R-salbutamol will potentially be an excellent drug candidate for rescue
therapy of the distressed horse, to improve airway function in low-grade airway
obstruction when administered before non-competitive exercise and to facilitate the
delivery of aerosol corticosteroids to improve steroid distribution in the lung,” indicated
Professor Edward Robinson of Michigan State University (MSU).

Pulmovet is the European joint venture company between Stirling and the Danish
company Equine HealthCare ApS. Pulmovet is leading the development of Stirling’s R-
salbutamol for the heaves application in combination with the specialised delivery
system, the EquineHaler™.

“Formulation studies and trials will continue through the second quarter of 2007 and it is
our intention to have a regulatory filing for submission for the drug/device combination in
the United States and Europe in 2008,” commented Dr London.


About the Trial:
The trial was conducted as part of the investigation of the dose-response to R-
salbutamol. It was performed under the direct supervision of Professor Edward
Robinson who is an internationally recognised equine veterinarian specialising in
pulmonary (lung) function and disorders in horses. MSU runs one of the largest equine
clinics in the US and has been associated with several important areas of research and
development in terms of equine medicine.


ENDS.


About Stirling Products:
Stirling Products is commercialising a number of patented applications in the area of
animal health. Apart from growth promoters that increase meat production while
decreasing fat accumulation in the animals, Stirling is also developing several treatments
for respiratory problems in horses (through a joint venture Pulmovet ApS in Europe) and
a treatment for obesity in companion animals.

For further information about this announcement or Stirling Products please contact Dr
London on (08) 9480 1480 or (0)400 204616. Additional information may be found on
the Company website http://www.stirlingproducts.net.




                                         ABN 32 077 105 429
                      Level 11, BGC Centre, 28 The Esplanade, Perth WA 6000
                                Tel: 08 9480 1480 Fax: 08 9226 4144
About Pulmovet ApS:
Pulmovet ApS is a joint venture between Stirling and the Danish company Equine
HealthCare ApS. Pulmovet has already established a presence in the treatment of
horse respiratory disorders through the worldwide use of the EquineHaler™. The newly
formed partnership (Pulmovet) will develop a range of drug/device combinations for
international markets to treat equine respiratory disorders commencing with the use of
R- salbutamol and the EquineHaler™.

For further information about this announcement or Pulmovet ApS please contact Calvin
London on (08) 9480 1480 or (0)400 204616 or visit www.pulmovet.com.




                                       ABN 32 077 105 429
                    Level 11, BGC Centre, 28 The Esplanade, Perth WA 6000
                              Tel: 08 9480 1480 Fax: 08 9226 4144

								
To top